Contact Information & Support Resources

Contact Information

For questions, contact Clinical Services at (888) 552-8988 opt. 1, Monday through Friday from 5:30am to 5pm Pacific Time (PT) or email

To learn more about the Adaptive Assist™ Patient Support Program or if you have questions about billing, visit or call (855) 236-9230, Monday through Thursday from 9am to 7pm and Friday 9am to 5pm Eastern Time (ET).

Adaptive Biotechnologies Corporation
Attention: CLIA Lab
1551 Eastlake Avenue East, Suite 200
Seattle, WA 98102

Intake Hours: Monday–Saturday 8am to 5pm Pacific Time

Biological specimens can be received and accessioned on the days and times above. Samples cannot currently be received on Sundays.

Click here to view our CAP Accreditation or our CLIA license.

Click here to access our Diagnostic Portal. If you do not have an account for our Diagnostic Portal, you may request one.


Technical Summary
Download the clonoSEQ Technical Summary.

clonoSEQ HCP Brochure
Provides a broad overview of how the clonoSEQ Assay works and what to expect for the ordering and reporting process.

Testing Service FAQs
Addresses common questions from HCPs when ordering clonoSEQ.

clonoSEQ Clinical Reports One Pager
Provides a one page summary of the clinical report.

clonoSEQ Clinical Reports Walkthrough
Provides a more in-depth tutorial on the clinical report.

Adaptive Assist Patient Support Program Clinician FAQ
Provides frequently asked questions and answers on billing and coverage for physicians interested in Adaptive Assist™ Patient Support Program.

Patient FAQ on Adaptive Assist Patient Support Program
Provides answers to patients’ commonly-asked questions about Adaptive’s billing program.

clonoSEQ Patient Brochure
Provides a description of what MRD is and how clonoSEQ works, in patient-friendly language.

Adaptive Assist Brochure
Provides a description of the patient support program and how to apply.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit